Fresenius Medical Care AG & Co. KGaA logo

Fresenius Medical Care AG & Co. KGaA

FMS

NYSEHealthcareMedical - Care Facilities

Previous close

$23.43

$0.00 · 0.00%

Aug 21, 4:00 PM ET

FMS company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Buy

Favorable setup — positive multi-factor alignment

Valuation

89

Deep Value

Momentum

43

Neutral

Sentiment

48

Mixed

Risk resilience

71

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. Through an extensive network of outpatient clinics, it delivers essential dialysis therapy along with laboratory and diagnostic support. For home-based care, the company supplies necessary equipment, provides comprehensive training, and offers ongoing patient assistance, including clinical oversight and coordinating supply deliveries directly to patients. In the United States, Fresenius Medical Care also contracts with hospitals to provide vital dialysis interventions for hospitalized individuals suffering from end-stage renal disease (ESRD) and acute kidney failure. Beyond services, it is a prominent developer, manufacturer, and distributor of a broad range of dialysis products. This portfolio encompasses polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers and solutions, concentrates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, the company produces non-dialysis medical devices, including acute cardiopulmonary and apheresis products. Its pharmaceutical division focuses on developing, acquiring, and in-licensing specialized renal medications, distributing these essential drugs and supplies to both individual patients' homes and dialysis centers. The company also extends its medical offerings to include a variety of specialized services such as vascular, cardiovascular, and endovascular care, operating ambulatory surgery centers for vascular procedures, and providing physician services in nephrology and cardiology. Products are sold directly to dialysis clinics, hospitals, and specialized treatment centers, complemented by sales through local teams, independent distributors, dealers, and agents. By February 23, 2022, Fresenius Medical Care managed an impressive network of 4,171 outpatient dialysis clinics across roughly 150 countries. Established in 1996, the company maintains its headquarters in Bad Homburg, Germany.

Industry
Medical - Care Facilities
Sector
Healthcare
Headquarters
DE
CEO
Helen Giza
Listed since
Sep 17, 1996
Employees
108,165

Market position

Day range

Current $23.43

52-week range

Current $23.43

Open
$23.455
Previous close
$23.43
Volume
791.56K
1.05× average
Average volume
751.83K
Average daily volume
Market cap
12.58B USD
Beta
0.75
Market reference 1
50-day average
$23.9192
-2.05% below average
200-day average
$23.1578
+1.18% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
21B EUR
P/E (TTM)
12.09×
P/B (TTM)
0.86×
P/S (TTM)
0.55×
EV / EBITDA
6.18×
Earnings yield
8.29%
Free cash flow yield
14.36%
Dividend yield
3.71%

Profitability & efficiency

Gross margin
26.36%
Operating margin
10.69%
Net margin
4.83%
Return on equity
6.85%
Return on assets
3.16%
Return on invested capital
5.34%

Financial health

Debt / equity
0.87×
Current ratio
1.26×
Altman Z-score
1.74
Piotroski F-score
8 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends30%20%10%0%Gross margin, FY2021: 27.09%Gross margin, FY2022: 25.23%Gross margin, FY2023: 25.32%Gross margin, FY2024: 24.60%Gross margin, FY2025: 25.62%Operating margin, FY2021: 10.51%Operating margin, FY2022: 7.79%Operating margin, FY2023: 7.04%Operating margin, FY2024: 7.59%Operating margin, FY2025: 9.31%Net margin, FY2021: 5.50%Net margin, FY2022: 3.47%Net margin, FY2023: 2.57%Net margin, FY2024: 2.78%Net margin, FY2025: 4.98%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 27.09%. Gross margin FY2022 25.23%. Gross margin FY2023 25.32%. Gross margin FY2024 24.60%. Gross margin FY2025 25.62%. Operating margin FY2021 10.51%. Operating margin FY2022 7.79%. Operating margin FY2023 7.04%. Operating margin FY2024 7.59%. Operating margin FY2025 9.31%. Net margin FY2021 5.50%. Net margin FY2022 3.47%. Net margin FY2023 2.57%. Net margin FY2024 2.78%. Net margin FY2025 4.98%.

Income trends

Revenue

19.63B EUR+1.51%

Operating income

1.83B EUR+24.50%

Net income

978.37M EUR+81.88%
Income trends across reported periods21.54B EUR13.89B EUR6.24B EUR−1.41B EURRevenue, FY2021: 17.62B EURRevenue, FY2022: 19.4B EURRevenue, FY2023: 19.45B EURRevenue, FY2024: 19.34B EURRevenue, FY2025: 19.63B EUROperating income, FY2021: 1.85B EUROperating income, FY2022: 1.51B EUROperating income, FY2023: 1.37B EUROperating income, FY2024: 1.47B EUROperating income, FY2025: 1.83B EURNet income, FY2021: 969.31M EURNet income, FY2022: 673.41M EURNet income, FY2023: 499M EURNet income, FY2024: 537.91M EURNet income, FY2025: 978.37M EURFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 17.62B EUR. Revenue FY2022 19.4B EUR. Revenue FY2023 19.45B EUR. Revenue FY2024 19.34B EUR. Revenue FY2025 19.63B EUR. Operating income FY2021 1.85B EUR. Operating income FY2022 1.51B EUR. Operating income FY2023 1.37B EUR. Operating income FY2024 1.47B EUR. Operating income FY2025 1.83B EUR. Net income FY2021 969.31M EUR. Net income FY2022 673.41M EUR. Net income FY2023 499M EUR. Net income FY2024 537.91M EUR. Net income FY2025 978.37M EUR.
Metric (EUR)FY2025FY2024FY2023FY2022FY2021
Revenue19.63B EUR19.34B EUR19.45B EUR19.4B EUR17.62B EUR
Cost of goods sold14.6B EUR14.58B EUR14.53B EUR14.5B EUR12.85B EUR
Gross profit5.03B EUR4.76B EUR4.93B EUR4.89B EUR4.77B EUR
Research and development157.98M EUR183.49M EUR231.97M EUR228.62M EUR220.78M EUR
Selling, general, and administrative3.03B EUR3.14B EUR3.2B EUR3.17B EUR2.77B EUR
Operating expenses3.2B EUR3.29B EUR3.56B EUR3.38B EUR2.92B EUR
Interest income69.61M EUR71.58M EUR88.22M EUR67.66M EUR73.17M EUR
Interest expense384.41M EUR407.04M EUR424.64M EUR360.14M EUR353.6M EUR
Depreciation and amortization1.5B EUR1.74B EUR1.75B EUR1.84B EUR1.62B EUR
Operating income1.83B EUR1.47B EUR1.37B EUR1.51B EUR1.85B EUR
Net income978.37M EUR537.91M EUR499M EUR673.41M EUR969.31M EUR

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
82%
9 beats, 1 miss, 1 met estimate
Average EPS surprise
+13.14%
11 comparable reports
Latest EPS result
0.66
Estimate 0.62 · Beat by 7.14%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.870.70.540.37Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 25, 2025: actual 0.48, estimate 0.41, surprise +17.07%, Beat. Q2 2025, reported May 6, 2025: actual 0.44, estimate 0.43, surprise +2.33%, Beat. Q3 2025, reported Aug 5, 2025: actual 0.52, estimate 0.5, surprise +4.00%, Beat. Q4 2025, reported Nov 4, 2025: actual 0.64, estimate 0.59, surprise +8.47%, Beat. Q1 2026, reported Feb 24, 2026: actual 0.83, estimate 0.647, surprise +28.28%, Beat. Q2 2026, reported May 5, 2026: actual 0.53, estimate 0.59, surprise -10.17%, Miss. Q3 2026, reported Aug 3, 2026: actual 0.66, estimate 0.616, surprise +7.14%, Beat. Q4 2026, reported Nov 3, 2026: actual —, estimate 0.607, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates6.21B5.61B5.01B4.42BQ1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 25, 2025: actual 5.27B USD, estimate 4.66B USD, surprise +13.10%, Beat. Q2 2025, reported May 6, 2025: actual 5.35B USD, estimate 5.06B USD, surprise +5.77%, Beat. Q3 2025, reported Aug 5, 2025: actual 5.64B USD, estimate 4.98B USD, surprise +13.37%, Beat. Q4 2025, reported Nov 4, 2025: actual 5.72B USD, estimate 4.8B USD, surprise +19.23%, Beat. Q1 2026, reported Feb 24, 2026: actual 5.97B USD, estimate 5.67B USD, surprise +5.26%, Beat. Q2 2026, reported May 5, 2026: actual 5.4B USD, estimate 5.41B USD, surprise -0.14%, Miss. Q3 2026, reported Aug 3, 2026: actual 5.6B USD, estimate 5.48B USD, surprise +2.22%, Beat. Q4 2026, reported Nov 3, 2026: actual —, estimate 5.71B USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$23.57

0.60% upside
Past 12 months12-month forecastHigh $25.80Average $23.57Low $19.90

Rating distribution

21 ratings
Strong buy00%
Buy524%
Hold1467%
Sell210%
Strong sell00%

Recent analyst actions

6 institutions
BernsteinmaintainMarket Perform
Goldman SachsdowngradeBuyNeutral
B of A SecuritiesdowngradeNeutralUnderperform
UBSdowngradeNeutralSell
HSBCupgradeReduceHold

Corporate actions

Annual dividends per share

Cash distributions grouped by calendar year; partial years are marked.

$0.815

2025 complete year-2.3% since 2021

2026 partial: $0.8644

* Partial calendar year in the available dividend history.

Corporate action history

Dividend

Ex-dividend May 22, 2026

$0.8644

Annual

Record May 22, 2026 · Payment Jun 8, 2026

Dividend

Ex-dividend May 23, 2025

$0.815

Annual

Record May 23, 2025 · Payment Jun 6, 2025

Dividend

Ex-dividend May 17, 2024

$0.6342

Annual

Record May 20, 2024 · Payment Jun 3, 2024

Dividend

Ex-dividend May 17, 2023

$0.6181

Annual

Record May 18, 2023 · Payment Jun 1, 2023

Dividend

Ex-dividend May 13, 2022

$0.7093

Annual

Record May 16, 2022 · Payment May 27, 2022

Dividend

Ex-dividend May 24, 2021

$0.8338

Annual

Record May 25, 2021 · Payment Jun 7, 2021

ETFs holding FMS

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research FMS

research.disclaimer